Open-Label Placebos Seem to Have Positive Clinical Effect

This article originally appeared here.
Share this content:
Open-Label Placebos Seem to Have Positive Clinical Effect
Open-Label Placebos Seem to Have Positive Clinical Effect

MONDAY, May 8, 2017 (HealthDay News) -- Compared with no treatment, open-label placebos seem to have a positive clinical effect, according to a review published online April 27 in the Journal of Evidence-Based Medicine.

James E.G. Charlesworth, Ph.D., from the University of Oxford in the United Kingdom, and colleagues conducted a systematic review and meta-analysis to examine the clinical efficacy of open-label placebos versus no treatment. Five trials, with 260 participants, met the inclusion criteria.

The clinical conditions assessed in the trials included irritable bowel syndrome, depression, allergic rhinitis, back pain, and attention deficit hyperactivity disorder. The researchers found that there was a moderate risk of bias in the trials. The effect of non-deceptive placebos was positive (standardized mean difference, 0.88; 95 percent confidence interval, 0.62 to 1.14; P < 0.00001; I² = 1 percent).

"Open-label placebos appear to have positive clinical effects compared to no treatment. Caution is warranted when interpreting these results due the limited number of trials identified, lack of assessor blinding, and the fact that positive messages were included alongside open-label placebos," the authors write. "Larger definitive trials are now warranted to explore the potential patient benefit of open-label placebos, to investigate the relative contributions of positive suggestions, and ethical implications."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Cost-Effectiveness of PCSK9 Inhibitors Called Into Question

Cost-Effectiveness of PCSK9 Inhibitors Called Into Question

Researchers say price would have to be between $4,000 and $5,000 per year to be cost-effective

Vitamin B6, B12 Supplements May Up Risk of Lung Cancer in Men

Vitamin B6, B12 Supplements May Up Risk of ...

Increased odds only seemed to affect men or male smokers

Tablet Use Encourages Patients to Explore Diabetes Risk

Tablet Use Encourages Patients to Explore Diabetes Risk

Replacing magazines with tablets can help patients learn about diabetes risk, take preventive action

is free, fast, and customized just for you!

Already a member?

Sign In Now »